Actuate Therapeutics is a private clinical stage biopharmaceutical company dedicated to developing innovative treatments for cancer and inflammatory diseases that can lead to fibrosis. The company's main focus is on the GSK-3β enzyme, also known as glycogen synthase kinase-3β, which has led to the development of their therapeutic candidate, elraglusib, formerly known as 9-ING-41. Elraglusib has shown great potential in the treatment of various types of cancer, either as a standalone treatment or in combination with other cancer therapies like chemotherapy and immune modulators.

Actuate Therapeutics strongly believes that this versatile agent can significantly improve clinical outcomes for patients with advanced and hard-to-treat cancers. Led by an experienced leadership team and supported by a competent board of directors and scientific advisory board, Actuate Therapeutics is committed to making a difference in the lives of patients. They are also open to partnering with academic and scientific organizations to further enhance their therapies and continue their research and development efforts